posted
Millenia Hope Acquires AIDS Patent 2/28/2006
World Class Scientists Head Millenia Subsidiary
WILMINGTON, Del., Feb 28, 2006 /PRNewswire-FirstCall via COMTEX/ -- Millenia Hope Inc., a biopharma corporation (OTC Bulletin Board: MLHP), has acquired a patent (pending) on AIDS that specifically describes compounds that inhibit HIV-1 RNase_H. The viral RNase_H has been shown to be essential for HIV replication. There are no inhibitors of HIV-1 RNase_H in clinical development at this time. In fact, very few such inhibitors have even been identified for this target. Successful development of this drug will play an important role in the treatment of AIDS patients who have become resistant to current therapy. Projected revenue for an orally bio-available (first in class) drug for AIDS is estimated at $350-$500 million US. The current market of AIDS drugs is $6 billion US, estimated to reach $10 billion by 2010. RNase_H preliminary results were presented at a major AIDS conference in Boston in 2005 to great interest from several large pharmaceutical and biotech companies.
Furthermore, Leonard Stella, Chairman & CEO of Millenia Hope is pleased to announce that its subsidiary's (MH-B) acquisition of the operations and technological expertise of the former Avance Pharma has been seamlessly implemented. MH-B is headed by a group of scientists, renowned in their fields of expertise:
Jean Archambault, Ph.D., MBA
President & COO-Director of Millenia Hope BioPharma (MH-B)
Founder of Avance Pharma, Dr. Archambault has been instrumental in developing and implementing the Company's unique drug discovery technology platform and creating the world's largest library of plant cell cultures. Prior to founding Avance Pharma, Dr. Archambault was a professor and department head of Chemical Engineering at the University of Quebec. Previously, Dr. Archambault headed the Cell Culture Group at the National Research Council of Canada's Biotechnology Research Institute where he developed and directed all mammalian, insect and plant cell bioengineering R&D activities.
Bahige Baroudy, Ph.D.
President & Chief Science Officer-Director of Millenia Hope Inc.
Chief Science Officer-Director of Millenia Hope BioPharma (MH-B)
Dr. Baroudy has multi-disciplinary expertise in basic research, infectious disease drug discovery and virology. Prior to joining Avance Pharma, Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and earned a place on "The Scientific American 50" list as the top Research Leader in 2003 in this category. He was also the Director, Division of Molecular Virology at the James N. Gamble Institute of Medical Research, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. Dr. Baroudy has also worked at the NIH in several disciplines.
Robert Williams, Ph.D.
Chief Development Officer-Director of Millenia Hope BioPharma (MH-B)
Dr. Williams, one of the co-founders of Avance Pharma, has been instrumental in the development of Avance Pharma's cell culture facility and in all aspects of the generation of Avance Pharma's proprietary library of purified fractions. His extensive cell culture expertise has now turned towards the generation of cell lines from selected plant species for the industrial production of biochemicals of interest to pharmaceutical and cosmetic companies. He has published numerous papers on all aspects of cell culture metabolism and metabolite production.
-------------------- Trading is a blast!! Posts: 4921 | From: Rhode Island | Registered: May 2005
| IP: Logged |
posted
Have you noticed that the bid is 0.11 and the ask is 0.1. Is this the sign of a mover?
Posts: 949 | From: Little Rock, AR | Registered: Dec 2005
| IP: Logged |
Stuck between naming th boat Day-Trading...or THX. MATTO
LOL...
this could have a nice run...
-------------------- I teach in the middle of a cornfield-Do your own DD and don't base your investments on my opinions Posts: 599 | From: AmishLand, PA | Registered: Jan 2006
| IP: Logged |
posted
Last trade was on 2-24, is that a little strange for a penny or just no interest til this news?
Posts: 196 | From: Bradenton, FL | Registered: Nov 2005
| IP: Logged |
posted
The first true drug to inhibit HIV,,,,,,This will be huge. Only 108M in the float. Face it or not HIV and AIDS is spreading and has to be addressed and this maybe the first HUGE step in doing just that. And with a patent on this process, the company has great growth potential.
Posts: 434 | From: NEBRASKA | Registered: Feb 2005
| IP: Logged |
posted
With only 108M float and a new patent that the world needs,,,,,,,,the potential is awesome
Millenia Hope Acquires AIDS Patent 2/28/2006
World Class Scientists Head Millenia Subsidiary
WILMINGTON, Del., Feb 28, 2006 /PRNewswire-FirstCall via COMTEX/ -- Millenia Hope Inc., a biopharma corporation (OTC Bulletin Board: MLHP), has acquired a patent (pending) on AIDS that specifically describes compounds that inhibit HIV-1 RNase_H. The viral RNase_H has been shown to be essential for HIV replication. There are no inhibitors of HIV-1 RNase_H in clinical development at this time. In fact, very few such inhibitors have even been identified for this target. Successful development of this drug will play an important role in the treatment of AIDS patients who have become resistant to current therapy. Projected revenue for an orally bio-available (first in class) drug for AIDS is estimated at $350-$500 million US. The current market of AIDS drugs is $6 billion US, estimated to reach $10 billion by 2010. RNase_H preliminary results were presented at a major AIDS conference in Boston in 2005 to great interest from several large pharmaceutical and biotech companies. Posts: 434 | From: NEBRASKA | Registered: Feb 2005
| IP: Logged |
posted
Volume starting on this one,,,,,,at high volume for the week and will probably close with highest volume for the year at this rate. You know what they say, first volume then pps.
Posts: 434 | From: NEBRASKA | Registered: Feb 2005
| IP: Logged |
posted
It will run when it gets noticed. The PR today should have made it run but to be truthful there are alot of subpennies that are being pumped right now and they are catching all of the attention. The float on this one is only 108M so when it gets noticed it will run good. Now is a good time to pick some up because once it starts up with this low of float it problably won't be back down here. IMO,,, get it while you can. The world needs this product and they will pay it's just takes time like everything else.
Posts: 434 | From: NEBRASKA | Registered: Feb 2005
| IP: Logged |
posted
Casp That would be great to get some independent thoughts on the product here. Thanks for the initiative.
Posts: 434 | From: NEBRASKA | Registered: Feb 2005
| IP: Logged |
posted
Looks like the company has no/very little revenue. I will keep watching this. The best thing to happen to this company will be if some big company buys it.
The Malaria drug is already out there trying to gain a market share. ( thats a plus but also the competition is the big boys who have been arround for years)
I'm not sure how much this PR was worth. The PR does not say if they have developed a drug based on this patent. The PR does not even mention if they have started in this direction. I think all they have done is presented a paper and got this patent (pending).
Here is the deal if they have not started developing the drug will take them more than 7 years to develop something and get it approved by FDA and make it to the market. This is a long process 3 phases and approval ( I think ). In some cases approval can be accelerated and this drug will definately qualify under that (but there is no short cut in the 3 phases ).
The patent is a good thing.
I tried calling my friends but these guys work late hours in the lab. I will find out how strong this patent is remember the possibility of some other company finding some other inhibitor.
This company is definately worth watching long term. My strategy would be to let the news fade away and let it drop and then get it.
posted
I agree that development of the drug will take time. Some testing has to have been done to get the results needed for presentation to large pharmaceutical and biotech companies. That is what is exciting about this, the buyout opportunities. It will take a large company to develop this, but I still believe the world needs this and the pharmaceutical companies will grab at the opportunities here. If the patent is granted $12M valuation on this company would be extremely cheap. I think the price goes up from here--------depending on, as you aluded to Casp, the exclusivity of the patent.
FROM THE PR
"RNase_H preliminary results were presented at a major AIDS conference in Boston in 2005 to great interest from several large pharmaceutical and biotech companies."Posts: 434 | From: NEBRASKA | Registered: Feb 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
